Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models.
about
Nanotechnology-based inhalation treatments for lung cancer: state of the artApproaches to improve the oral bioavailability and effects of novel anticancer drugs berberine and betulinic acid.Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma.Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer.Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancerNO-dependent attenuation of TPA-induced immunoinflammatory skin changes in Balb/c mice by pindolol, heptaminol or ATRA, but not by verapamil.Inhalable oridonin-loaded poly(lactic-co-glycolic)acid large porous microparticles for in situ treatment of primary non-small cell lung cancer.Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC).Novel diindolylmethane derivatives based NLC formulations to improve the oral bioavailability and anticancer effects in triple negative breast cancer.Combination Approach of YSA Peptide Anchored Docetaxel Stealth Liposomes with Oral Antifibrotic Agent for the Treatment of Lung Cancer.Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunitiesReversal of drug-resistance by noscapine chemo-sensitization in docetaxel resistant triple negative breast cancer.Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.Telmisartan inhibits NSCLC A549 cell proliferation and migration by regulating the PI3K/AKT signaling pathway.An Adaptogen: Withaferin A Ameliorates in Vitro and in Vivo Pulmonary Fibrosis by Modulating the Interplay of Fibrotic, Matricelluar Proteins, and Cytokines.
P2860
Q26774177-55A803DF-ECEC-47C8-A290-D4C76F0F1640Q35116352-E0BA1DE0-78A8-43F7-812E-7AA1469F774BQ36641553-6099634A-B8D3-4A6E-84D4-255A875C5592Q37013337-D16A7B45-86D3-4A61-8BBE-84205A9B8797Q37426564-B2C0BD7A-C533-47BA-98D5-F3ADBC6FA265Q37565209-6A0A1BB3-86AC-4B54-ADD7-FBFFEDD395A3Q37587394-0798B6B0-B30D-4685-A4F3-2F1FA0C5B900Q38714359-301137B7-CDC8-4739-BCCC-293E566A219BQ38748639-D7871520-7CD1-44A0-A697-5B70E7D0A0A5Q38778869-F7E5DAC0-18C0-45F5-8412-71808170459CQ39306543-532A445D-2670-424E-A79F-E5EFD228873EQ47311101-2D3B78B0-467D-4EFE-8322-BB45399CFA28Q47863448-CAB834D3-2BEA-49BA-A675-838021FD2362Q52649660-39B0FA4A-2057-44B0-8D06-26300DF7C560Q55073347-12569110-0243-4140-9F47-9F8BFC7CF137
P2860
Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inhalation delivery of Telmisa ...... rticles in lung cancer models.
@en
Inhalation delivery of Telmisa ...... rticles in lung cancer models.
@nl
type
label
Inhalation delivery of Telmisa ...... rticles in lung cancer models.
@en
Inhalation delivery of Telmisa ...... rticles in lung cancer models.
@nl
prefLabel
Inhalation delivery of Telmisa ...... rticles in lung cancer models.
@en
Inhalation delivery of Telmisa ...... rticles in lung cancer models.
@nl
P2093
P2860
P1476
Inhalation delivery of Telmisa ...... rticles in lung cancer models.
@en
P2093
Apurva R Patel
Chandraiah Godugu
Mandip Singh
Ravi Doddapaneni
Srujan Marepally
Tanise Jackson
P2860
P356
10.1016/J.JCONREL.2013.06.036
P407
P577
2013-07-07T00:00:00Z